FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969656908> ?p ?o ?g. }

• W1969656908 endingPage "58" @default.
• W1969656908 startingPage "52" @default.
• W1969656908 abstract "Material and Methods. We retrospectively determined the efficacy and safety of a combination of bevacizumab and irinotecan in a consecutive series of 52 heavily pre-treated patients with recurrent high-grade brain tumours. Patients received bevacizumab (10 mg/kg) and irinotecan [340 mg/m2 for those receiving enzyme-inducing antiepileptic drugs (EIAEDs) and 125 mg/m2 for those not receiving EIAEDs] every 2 weeks. Fifty-two patients were included and 47 were evaluable for response. Results. Complete or partial response was observed in 25% of all cases (30% response in grade IV glioma and 15% in grade III glioma). Estimated median progression-free survival (PFS) for both grade IV and grade III glioma was 22 weeks. The 6-month PFS was 32% for all patients, 40% for grade IV glioma and 33% for grade III glioma. Estimated median overall survival was 30 weeks for all patients, 28 weeks for grade IV glioma and 32 weeks for grade III glioma. Four patients discontinued treatment because of unmanageable toxicity: cerebral haemorrhage, cardiac arrhythmia, intestinal perforation and diarrhoea, the latter resulting in death. Discussion. We conclude that the combination of bevacizumab and irinotecan shows acceptable safety and is a clinically relevant choice of therapy in heavily pre-treated patients with recurrent high-grade brain tumours." @default.
• W1969656908 created "2016-06-24" @default.
• W1969656908 creator A5000210163 @default.
• W1969656908 creator A5004172331 @default.
• W1969656908 creator A5007297826 @default.
• W1969656908 creator A5013790696 @default.
• W1969656908 creator A5054535048 @default.
• W1969656908 creator A5063764427 @default.
• W1969656908 creator A5077199450 @default.
• W1969656908 creator A5087170219 @default.
• W1969656908 date "2009-01-01" @default.
• W1969656908 modified "2023-09-26" @default.
• W1969656908 title "Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours" @default.
• W1969656908 cites W1858161324 @default.
• W1969656908 cites W1885167687 @default.
• W1969656908 cites W1940514332 @default.
• W1969656908 cites W1959628099 @default.
• W1969656908 cites W1970510435 @default.
• W1969656908 cites W1978041336 @default.
• W1969656908 cites W1995369709 @default.
• W1969656908 cites W1996810856 @default.
• W1969656908 cites W2002727873 @default.
• W1969656908 cites W2006202974 @default.
• W1969656908 cites W2014994637 @default.
• W1969656908 cites W2026408479 @default.
• W1969656908 cites W2031376430 @default.
• W1969656908 cites W2036564049 @default.
• W1969656908 cites W2049721139 @default.
• W1969656908 cites W2052138995 @default.
• W1969656908 cites W2058214932 @default.
• W1969656908 cites W2093783077 @default.
• W1969656908 cites W2096287682 @default.
• W1969656908 cites W2099808007 @default.
• W1969656908 cites W2113176208 @default.
• W1969656908 cites W2117188579 @default.
• W1969656908 cites W2121505472 @default.
• W1969656908 cites W2123604415 @default.
• W1969656908 cites W2127745545 @default.
• W1969656908 cites W2137832651 @default.
• W1969656908 cites W2139008103 @default.
• W1969656908 cites W2140510570 @default.
• W1969656908 cites W2145835533 @default.
• W1969656908 cites W2157270051 @default.
• W1969656908 cites W2157769714 @default.
• W1969656908 cites W2159378961 @default.
• W1969656908 cites W2160382843 @default.
• W1969656908 cites W2161637607 @default.
• W1969656908 cites W2166921825 @default.
• W1969656908 cites W2168414172 @default.
• W1969656908 cites W2395830793 @default.
• W1969656908 cites W33484130 @default.
• W1969656908 doi "https://doi.org/10.1080/02841860802537924" @default.
• W1969656908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19031176" @default.
• W1969656908 hasPublicationYear "2009" @default.
• W1969656908 type Work @default.
• W1969656908 sameAs 1969656908 @default.
• W1969656908 citedByCount "96" @default.
• W1969656908 countsByYear W19696569082012 @default.
• W1969656908 countsByYear W19696569082013 @default.
• W1969656908 countsByYear W19696569082014 @default.
• W1969656908 countsByYear W19696569082015 @default.
• W1969656908 countsByYear W19696569082016 @default.
• W1969656908 countsByYear W19696569082017 @default.
• W1969656908 countsByYear W19696569082018 @default.
• W1969656908 countsByYear W19696569082019 @default.
• W1969656908 countsByYear W19696569082020 @default.
• W1969656908 countsByYear W19696569082021 @default.
• W1969656908 countsByYear W19696569082022 @default.
• W1969656908 countsByYear W19696569082023 @default.
• W1969656908 crossrefType "journal-article" @default.
• W1969656908 hasAuthorship W1969656908A5000210163 @default.
• W1969656908 hasAuthorship W1969656908A5004172331 @default.
• W1969656908 hasAuthorship W1969656908A5007297826 @default.
• W1969656908 hasAuthorship W1969656908A5013790696 @default.
• W1969656908 hasAuthorship W1969656908A5054535048 @default.
• W1969656908 hasAuthorship W1969656908A5063764427 @default.
• W1969656908 hasAuthorship W1969656908A5077199450 @default.
• W1969656908 hasAuthorship W1969656908A5087170219 @default.
• W1969656908 hasConcept C121608353 @default.
• W1969656908 hasConcept C126322002 @default.
• W1969656908 hasConcept C141071460 @default.
• W1969656908 hasConcept C191897082 @default.
• W1969656908 hasConcept C192562407 @default.
• W1969656908 hasConcept C2776694085 @default.
• W1969656908 hasConcept C2777802072 @default.
• W1969656908 hasConcept C2778227246 @default.
• W1969656908 hasConcept C2778456384 @default.
• W1969656908 hasConcept C2778527123 @default.
• W1969656908 hasConcept C2780259306 @default.
• W1969656908 hasConcept C502942594 @default.
• W1969656908 hasConcept C526805850 @default.
• W1969656908 hasConcept C71924100 @default.
• W1969656908 hasConcept C90924648 @default.
• W1969656908 hasConceptScore W1969656908C121608353 @default.
• W1969656908 hasConceptScore W1969656908C126322002 @default.
• W1969656908 hasConceptScore W1969656908C141071460 @default.
• W1969656908 hasConceptScore W1969656908C191897082 @default.
• W1969656908 hasConceptScore W1969656908C192562407 @default.

• next